Bold Therapeutics Pursues Collaborators for Development of its Lead Drug for COVID-19 Treatment
The company is currently seeking interest from companies who have the skill and means to rapidly advance BOLD-100 for the treatment of COVID-19.
Bold Therapeutics, a clinical-stage biopharmaceutical company based in Canada, announced on March 27, 2020 that its lead drug BOLD-100 may have the potential to be used as a novel antiviral agent against COVID-19.
According to a company press release, the drug is an anti-resistance ruthenium-based small-molecule drug that restrains stress-induced upregulation of GRP78. Currently, the company is developing the drug in combination with FOLFOX and other anti-cancer agents for the treatment of gastrointestinal cancers but, after a recent publication in the Journal of Infection pinpointed GRP78 as a potential binding site for COVID-19, the company decided to explore its options, the press release said.
The company is currently seeking interest from companies who have the skill and means to rapidly advance BOLD-100 for the treatment of COVID-19.
Source: Bold Therapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
